TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‐altered metastatic hormone‐sensitive prostate cancer, including both BRCA and non‐BRCA alterations There was an estimated 77% probability of remaining progression-free at three years with TALZENNA plus XT...